Literature DB >> 19968913

Beneficial effects of denosumab for reducing risk of vertebral and nonvertebral fractures.

Chin Lee1.   

Abstract

Entities:  

Year:  2009        PMID： 19968913     DOI： 10.1007/s11914-009-0025-0

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN： 1544-1873            Impact factor:   5.096


× No keyword cloud information.
  6 in total

1.  Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Authors:  David L Kendler; Christian Roux; Claude Laurent Benhamou; Jacques P Brown; Michael Lillestol; Suresh Siddhanti; Hoi-Shen Man; Javier San Martin; Henry G Bone
Journal:  J Bone Miner Res       Date:  2010-01       Impact factor: 6.741

2.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

3.  Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.

Authors:  Jacques P Brown; Richard L Prince; Chad Deal; Robert R Recker; Douglas P Kiel; Luiz H de Gregorio; Peyman Hadji; Lorenz C Hofbauer; Jose M Alvaro-Gracia; Huei Wang; Matthew Austin; Rachel B Wagman; Richard Newmark; Cesar Libanati; Javier San Martin; Henry G Bone
Journal:  J Bone Miner Res       Date:  2009-01       Impact factor: 6.741

Review 4.  Osteoclasts and the immune system.

Authors:  Tomoki Nakashima; Hiroshi Takayanagi
Journal:  J Bone Miner Metab       Date:  2009-05-20       Impact factor: 2.626

5.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Authors:  S R Cummings; D M Black; D E Thompson; W B Applegate; E Barrett-Connor; T A Musliner; L Palermo; R Prineas; S M Rubin; J C Scott; T Vogt; R Wallace; A J Yates; A Z LaCroix
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272

6.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.